NCT06136195View on ClinicalTrials.gov

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

PHASE1RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Alcohol ConsumptionHeavy DrinkerAlcohol Use Disorder (AUD)
Interventions
DRUG

Mavoglurant

The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.

Trial Locations (2)

06511

RECRUITING

Connecticut Mental Health Center (SAC and SATU), New Haven

06512

RECRUITING

Yale New Haven Hospital, New Haven

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Yale University

OTHER